Clinical effectiveness of oral antiviral treatment for non-hospitalized high-risk patients with COVID-19 during Omicron JN.1 subvariant wave: a US-based propensity-matched cohort study
Oral antiviral agents significantly reduced the risk of adverse outcomes among high-risk COVID-19 patients during the Omicron JN.1 subvariant wave. These findings support the potential benefits of oral antiviral therapy in treating COVID-19, particularly in high-risk populations.
Authors
- Po‐Yu Huang (ORCID: https://orcid.org/0000-0002-8682-1322)
- Wan‐Hsuan Hsu (ORCID: https://orcid.org/0000-0002-2517-1792)
- Jheng-Yan Wu
- Ya‐Wen Tsai (ORCID: https://orcid.org/0000-0003-4630-3923)
- Ting-Hui Liu
- Min‐Hsiang Chuang (ORCID: https://orcid.org/0000-0002-8538-4861)
- Bo-Wen Shiau
- Shu-Farn Tey
- L. S. Hung
- Chih-Cheng Lai
Institutions
- Chi Mei Medical Center (TW)
- Fooyin University (TW)
- National Cheng Kung University (TW)
Publication Details
- Journal
- Pneumonia
- Published
- 2025-05-24
- DOI
- https://doi.org/10.1186/s41479-025-00168-w
- Citations
- 1
- Primary Topic
- COVID-19 Clinical Research Studies
- Type
- article
- Field-Weighted Citation Impact
- 1.40